@article{2d760b2341374281a2f53a79cc5d8c65,
title = "Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia",
abstract = "We present retrospective data on 140 patients treated with mCBAD (a high-dose modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone regimen) at our institution. More than 80% (120/140 patients) of patients received ≤2 cycles of mCBAD with best overall response ≥90% (very good partial response 18%-23%, and complete remission 7%-23%). Median overall survival from start date of mCBAD and treatment-related mortality were 14 months for relapsed patients: 8% (10/116; n = 116), 16 months for plasma cell leukemia: 9% (1/11; n = 11), and 35 months for newly diagnosed myeloma: 0% (n = 13). mCBAD response is short-lived and has high treatment-related mortality. It might be useful as a bridge to transplantation or cell therapies when other treatments are not available.",
keywords = "High-risk MM, Multiple myeloma, Newly diagnosed MM, Relapse/refractory MM, mCBAD",
author = "Samer Tabchi and Rajit Nair and Chutima Kunacheewa and Patel, {Krina K.} and Lee, {Hans C.} and Thomas, {Sheeba K.} and Behrang Amini and Sairah Ahmed and Mehta, {Rohtesh S.} and Qaiser Bashir and Qazilbash, {Muzzaffar H.} and Weber, {Donna M.} and Orlowski, {Robert Z.} and Raymond Alexanian and Lei Feng and Manasanch, {Elisabet E.}",
note = "Funding Information: This work was supported in part by The MD Anderson Cancer Center Support Grant ( P30 CA016672 ). Funding Information: E. Manasanch has received research support from Sanofi , Quest Diagnostics , Novartis , JW Pharma , and Merck , and consultant fees from Takeda, Celgene, Sanofi, Amgen, and BMS. H.C. Lee has received consulting fees from Adaptive Biotechnologies, Celgene, Piera, and Takeda, and research support from Amgen , Daiichi-Sankyo , Janssen , and Takeda . S. Thomas has received consulting fees from Amgen and research support from Acerta Pharma , Amgen , Array BioPharma , Bristol-Myers Squibb , Celgene , and Idera . M. Qazilbash has received research support from Janssen and BioLineRx, and consulting fees from Amgen. R.Z. Orlowski has received consulting fees from Amgen, Bristol-Myers-Squibb, Celgene, Janssen, Kite Pharma, Sanofi, and Takeda, and research support from Amgen , BioTheryX , and Spectrum Pharmaceuticals . The remaining authors have stated that they have no conflicts of interest. Funding Information: E. Manasanch has received research support from Sanofi, Quest Diagnostics, Novartis, JW Pharma, and Merck, and consultant fees from Takeda, Celgene, Sanofi, Amgen, and BMS. H.C. Lee has received consulting fees from Adaptive Biotechnologies, Celgene, Piera, and Takeda, and research support from Amgen, Daiichi-Sankyo, Janssen, and Takeda. S. Thomas has received consulting fees from Amgen and research support from Acerta Pharma, Amgen, Array BioPharma, Bristol-Myers Squibb, Celgene, and Idera. M. Qazilbash has received research support from Janssen and BioLineRx, and consulting fees from Amgen. R.Z. Orlowski has received consulting fees from Amgen, Bristol-Myers-Squibb, Celgene, Janssen, Kite Pharma, Sanofi, and Takeda, and research support from Amgen, BioTheryX, and Spectrum Pharmaceuticals. The remaining authors have stated that they have no conflicts of interest.This work was supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672). Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2019",
month = sep,
doi = "10.1016/j.clml.2019.05.001",
language = "English (US)",
volume = "19",
pages = "560--569",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "9",
}